퓨쳐켐

220100KOSDAQ의약품 제조업

50.8 / 100

Reference Date: 2026-07-24

Financial Score12.5 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure14.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 23.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

FutureChem develops radiopharmaceuticals by researching peptides similar to proteins specifically expressed in certain diseases, offering diagnostic and therapeutic drugs. Key products include FC303 for prostate cancer diagnosis and FC705 for treatment, leveraging theranostics technology for personalized medicine. The company utilizes the sCUBE® automated synthesis system to achieve GMP-level manufacturing standards.

Number of Employees

94people

Average Salary

53.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 11.234.0Point

PBR

3.23Industry Average 0.810.0Point

4.0x industry avg (risky)

ROE

-20.50Industry Average 4.010.0Point

Well below industry avg

Debt Ratio

9.30Industry Average 12.435.0Point

Lower than industry avg (good)

Trend 2023~20253.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.9% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲2.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.5% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 5Neutral 0Negative 0Average Sentiment Score 85

Positive
퓨쳐켐, '프로스타뷰' 베트남에 라이선스·공급계약
퓨쳐켐의 베트남 자회사와의 라이선스 및 공급계약 체결로 인해 매출 증대와 로열티 확보 기대.
Positive
퓨쳐켐, 베트남 HIC와 전립선암 진단 의약품 독점 공급계약
퓨쳐켐이 베트남 하노이조사센터와의 독점 공급계약 체결로 전립선암 진단 시장 진출 확대 기대.
Positive
케이메디허브, 제 43호 국산 신약 전립선암진단용 방사선 의약품 허가....
퓨쳐캠의 신약 개발 허가 소식으로 인해 주가 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 7,890Won52-week high 34,20052-week low 7,310

1-month return0.0Point

1m -23.62% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

7 totalPositive 2Neutral 5Negative 0

Neutral[발행조건확정]증권신고서(지분증권)2026-07-14
Positive유상증자1차발행가액결정2026-07-14
Positive권리락 (유상증자)2026-07-14
Neutral[기재정정]투자설명서2026-07-14
Neutral[기재정정]주요사항보고서(유무상증자결정)2026-07-14